Navigation Links
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Date:1/31/2008

uct lines; from sale or write-down of equity investments and from discontinuations of operations; restructuring items that meet the requirements of SFAS 112 for severance and SFAS 146 for other exit costs; accelerated depreciation charges under SFAS 144 related to restructuring items described above; asset impairments; charges and recoveries relating to significant legal proceedings; upfront and milestone payments for in-licensing of products that have not achieved regulatory approval that are immediately expensed; co promotion or alliance charges and payments for in- process research and development which under GAAP are immediately expensed rather than amortized over the life of the agreement; income from upfront and milestone payments that is immediately recognized for out-licensing of products, including deferred income recognized upon termination; costs of early debt retirement; impairments to marketable securities; and significant tax events. This information is intended to enhance an investor's overall understanding of the company's past financial performance and prospects for the future. For example, non-GAAP earnings per share information is an indication of the company's baseline performance before items that are considered by the company to be not reflective of the company's ongoing results. In addition, this information is among the primary indicators the company uses as a basis for evaluating company performance, allocating resources, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for diluted earnings per share prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's fin
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... (PRWEB) May 27, 2015 SIMpalm ... helped its client to launch an Android version for ... merchants to accept credit, debit and ACH payments on ... Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . The iOS version ... has been recently updated by SIMpalm. , Forte ...
(Date:5/27/2015)... Get Tested Coachella Valley , a ... of HIV, will recognize its most influential, passionate and ... Ambassador Awards, to be held on Twitter on June ... first for public health campaigns, the online awards ceremony ... influencers for breaking down stigma, spreading awareness and educating ...
(Date:5/27/2015)... According to research conducted by Dr. Huay-Zong ... Dallas some migraine patients have an increased likelihood of ... apparently also have some shared risk factors -- particularly ... a history of diabetes and/or smoking. Both conditions were ... in particular was less common in Hispanics. , ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces ... business to better serve the needs of couples in Chicagoland. ... on the Northwest side of the city at 4920 North ... by calling the Chicago office at (773) 794–1818. This ... of Chicago. The other 2 offices are in Gurnee ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
Breaking Medicine News(10 mins):Health News:Forte Payment System Launches Android Version of Payment App 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2
... , THURSDAY, Sept. 29 (HealthDay News) -- One-quarter of American ... to new research from the U.S. Agency for Healthcare Research ... blood pressure, also known as hypertension, 29 percent were black ... federal agency noted in its Sept. 27 News and ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Campus-wide smoking bans ... habit, new research suggests. The finding stems from a ... a ban and one without. "Although we haven,t pinpointed ... most to the positive changes in students, smoking rates, having ...
... DCThrough the identification of a gene,s impact on a ... continue to make progress in understanding the mechanics ... of white matter, known as myelination. The study, published ... of The Journal of Neuroscience , identified Sox17 ...
... might think, cancer and diabetes appear to have some biology in ... the Cell Press journal, Cell, a pathway that initially ... also influences the odds that mice develop or resist diabetes. ... Lin28b become more sensitive to insulin and less prone to diabetes ...
... , HOUSTON, Sept. 29, 2011 Hormone researchers at ... on providing long-term treatment options for diabetes, obesity and ... naturally occurring estrogen. They now believe that ... body functions in both females and males. While estradiol ...
... 28, 2011 - (BRONX, NY) - People taking oral steroids ... severe vitamin D deficiency, according to a study of more ... Albert Einstein College of Medicine of Yeshiva University. Their ... of Clinical Endocrinology and Metabolism, suggest that physicians should more ...
Cached Medicine News:Health News:1 in 4 U.S. Adults Treated for High Blood Pressure: Report 2Health News:Campus Smoking Bans May Help College Students Quit 2Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Diabetes and cancer: A shared biological basis 2Health News:UH researchers explain hormonal role in glucose and fat metabolism 2Health News:Oral steroids linked to severe vitamin D deficiency in nationwide study 2
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... 3 GIFT-I study of its investigational, all-oral, interferon ... with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the ... Japan . 1 GIFT-I evaluated genotype ... Japanese patients, with and without cirrhosis, who were ...
(Date:5/26/2015)... Calif. , May 26, 2015 Thoratec ... mechanical circulatory support therapies to save, support and restore ... Goldman Sachs 36 th Annual Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight time (5:00 p.m., Eastern Daylight Time). ...
(Date:5/26/2015)... , May 26, 2015  Amgen (NASDAQ: ... from the Phase 3 OPTiM study in the ... The data published in JCO , which ... American Society of Clinical Oncology (ASCO) in 2013 and ... in patients with unresected stage IIIB, IIIC or IV ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
5 inch (12.7 cm), 2 x 5 mm blade....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Nicati foreign body spud....
Foreign body spud angled, lightly rounded tip....
Medicine Products: